South Delhi Pharma, New Delhi, India
MYLOTARG ™ (gemtuzumab ozogamicin) for injection
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
MYLOTARG is a prescription medicine. MYLOTARG is used to treat leukemia (CD33-positive acute myeloid leukemia-AML).
INDICATIONS AND USAGE
MYLOTARG is a CD33-directed antibody-drug conjugate indicated for:
• treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults.
• treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older.
DOSAGE FORMS & STRENGTHS
For Injection: 4.5 mg as a lyophilized cake or powder in a single-dose vial for reconstitution and dilution.
Manufactured By: Pfizer Inc
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “MYLOTARG ™ (gemtuzumab ozogamicin) for injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Gemtuzumab ozogamicin, sold under the brand name Mylotarg, is an antibody-drug conjugate (a drug-linked monoclonal antibody) that is used to treat acute myeloid leukemia.
In the United States, gemtuzumab ozogamicin is indicated for newly diagnosed CD33-positive acute myeloid leukemia (AML) for adults and children one month and older and for the treatment of relapsed or refractory CD33-positive AML in adults and children two years and older.
